Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)
- Authors:
- Mark A. Baxter
- Russell D. Petty
- Daniel Swinson
- Peter S. Hall
- Shane O'Hanlon
-
Affiliations: Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD2 1SY, Scotland, UK, Department of Oncology, St. James's Hospital, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, Scotland, UK, Department of Geriatric Medicine, St. Vincent's University Hospital, Dublin 4, D04 N2E0, Republic of Ireland - Published online on: March 17, 2021 https://doi.org/10.3892/ijo.2021.5202
- Article Number: 22
-
Copyright: © Baxter et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Edgren G, Adami HO, Weiderpass E and Nyrén O: A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 62:1406–1414. 2013. View Article : Google Scholar | |
|
Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Munakata M and Sakata Y: Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res. 3:220–224. 2009. | |
|
Offman J, Pesola F and Sasieni P: Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. Br J Cancer. 118:1391–1398. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Merchant SJ, Brogly SB, Booth CM, Goldie C, Nanji S, Patel SV, Lajkosz K and Baxter NN: Palliative care and symptom burden in the last year of life: A population-based study of patients with gastrointestinal cancer. Ann Surg Oncol. 26:2336–2345. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ and Young J: The prevalence and outcomes of frailty in older cancer patients: A systematic review. Ann Oncol. 26:1091–1101. 2015. View Article : Google Scholar | |
|
Besharat S, Jabbari A, Semnani S, Keshtkar A and Marjani J: Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol. 14:3725–3728. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fontana E and Smyth EC: Novel targets in the treatment of advanced gastric cancer: A perspective review. Ther Adv Med Oncol. 8:113–125. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Partnership HQI: National Oesophago-Gastric Cancer Audit-An audit of the care received by people with oesophago-gastric cancer and oesophageal high grade dysplasia in England and Wales. 2019. | |
|
Swinson D, Hingorani M, Stokes Z, Dent J, Guptal K, Chatterjee A, Kamposioras K, Grumett SA, Khan M, Marshall H, et al: Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial. J Clin Oncol. 37:4051. 2019. View Article : Google Scholar | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemo-therapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Researc: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al: Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6:1571–1580. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Moehler M, Shitara S, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, et al: LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. 31(Suppl 4): S11912020. View Article : Google Scholar | |
|
Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, et al: A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastro-esophageal cancer (321GO). Br J Cancer. 116:472–478. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Swaminathan D and Swaminathan V: Geriatric oncology: Problems with under-treatment within this population. Cancer Biol Med. 12:275–283. 2015. | |
|
Trumper M, Ross P, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M and Hickish T: Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer. 42:827–834. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, et al: International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 32:2595–2603. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 8:CD0040642017.PubMed/NCBI | |
|
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Arends J: Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment-focusing on metabolism and supportive care. Annals of Oncology. 29(Suppl 2): ii27–ii34. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amarya S, Singh K and Sabharwal M: Changes during aging and their association with malnutrition. J Clin Gerontol Geriat. 6:78–84. 2015. View Article : Google Scholar | |
|
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S and Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet. 380:37–43. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cereda E, Pedrolli C, Klersy C, Bonardi C, Quarleri L, Cappello S, Turri A, Rondanelli M and Caccialanza R: Nutritional status in older persons according to healthcare setting: A systematic review and meta-analysis of prevalence data using MNA(®). Clin Nutr. 35:1282–1290. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Boniface MM, Wani SB, Schefter TE, Koo PJ, Meguid C, Leong S, Kaplan JB, Wingrove LJ and McCarter MD: Multidisciplinary management for esophageal and gastric cancer. Cancer Manag Res. 8:39–44. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mills S, Buchanan D, Guthrie B, Donnan P and Smith B: Factors affecting use of unscheduled care for people with advanced cancer: A retrospective cohort study in Scotland. Br J Gen Pract. 69:e860–e868. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dalhammar K, Malmström M, Schelin M, Falkenback D and Kristensson J: The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study. PLoS One. 15:e02350452020. View Article : Google Scholar : PubMed/NCBI | |
|
Srivastava P: The benefits of early integration of palliative care as a part of standard outpatient oncology care. J Clin Oncol. 32:182014. View Article : Google Scholar | |
|
Vandebroek AJV and Schrijvers D: Nutritional issues in anti-cancer treatment. Ann Oncol. 19:v52–v55. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Laviano A, Di Lazzaro L and Koverech A: Nutrition support and clinical outcome in advanced cancer patients. Proc Nutr Soc. 77:388–393. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Eyigor S and Akdeniz S: Is exercise ignored in palliative cancer patients? World J Clin Oncol. 5:554–559. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS and Stark S: Systematic review of falls in older adults with cancer. J Geriatr Oncol. 6:70–83. 2015. View Article : Google Scholar : | |
|
Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol. 29:3457–3465. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wildes TM, Ruwe AP, Fournier C, Gao F, Carson KR, Piccirillo JF, Tan B and Colditz GA: Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol. 4:227–234. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Doganay E and Moorthy K: Prehabilitation for esophagectomy. J Thorac Dis. 11(Suppl 5): S632–S638. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Faithfull S, Turner L, Poole K, Joy M, Manders R, Weprin J, Winters-Stone K and Saxton J: Prehabilitation for adults diagnosed with cancer: A systematic review of long-term physical function, nutrition and patient-reported outcomes. Eur J Cancer Care (Engl). 28:e130232019. View Article : Google Scholar | |
|
Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE and Carli F: Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: A randomized clinical trial. JAMA Surg. 153:1081–1089. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hall CC, Cook J, Maddocks M, Skipworth RJE, Fallon M and Laird BJ: Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: A systematic review. Support Care Cancer. 27:2371–2384. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Research UK: Improving Cancer Treatment and Care for an Ageing Population: Cancer Research UK, London. 2018, https://www.cancerresearchuk.org/sites/default/files/advancing_care_advancing_years_full_report.pdf. Accessed November 4, 2020. | |
|
Soto-Perez-de-Celis E, Li D, Sun CL, Kim K, Twardowski P, Fakih M, Chung VM, Cristea CM, Lim D, Yuan Y, et al: Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT). J Clin Oncol. 36:100092018. View Article : Google Scholar | |
|
Cancer Research UK: Cancer mortality by age. https://www.cancer-researchuk.org/health-professional/cancer-statistics/mortality/age. Accessed November 3, 2020. | |
|
Popescu RA, Norman A, Ross PJ, Parikh B and Cunningham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 17:2412–2418. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, et al: The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the arbeitsgemeinschaft internistische onkologie (FLOT65+). Eur J Cancer. 49:835–842. 2013. View Article : Google Scholar | |
|
Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, et al: Frailty consensus: A call to action. J Am Med Dir Assoc. 14:392–397. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly CM and Shahrokni A: Moving beyond karnofsky and ECOG performance status assessments with New technologies. J Oncol. 2016:61865432016. View Article : Google Scholar : PubMed/NCBI | |
|
Kirkhus L, Šaltytė Benth J, Rostoft S, Grønberg BH, Hjermstad MJ, Selbæk G, Wyller TB, Harneshaug M and Jordhøy MS: Geriatric assessment is superior to oncologists' clinical judgement in identifying frailty. Br J Cancer. 117:470–477. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I and Mitnitski A: A global clinical measure of fitness and frailty in elderly people. CMAJ. 173:489–495. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Soubeyran P, Bellera CA, Gregoire F, Blanc J, Ceccaldi J, Mertens CBB, Mathoulin-Pélissier S, Fonck M and Rainfray M: Validation of a screening test for elderly patients in oncology. J Clin Oncol. 26:20568. 2008. View Article : Google Scholar | |
|
Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG, Sloss EM and Wenger NS: The vulnerable elders survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 49:1691–1699. 2001. View Article : Google Scholar | |
|
Overcash JA, Beckstead J, Extermann M and Cobb S: The abbreviated comprehensive geriatric assessment (aCGA): A retrospective analysis. Crit Rev Oncol Hematol. 54:129–136. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Steverink N, Slaets J, Schuurmans H and Lis M: Measuring frailty: Developing and testing the GFI (Groningen Frailty Indicator). Gerontologist. 41:236–237. 2001. | |
|
Rubenstein LZ, Stuck AE, Siu AL and Wieland D: Impacts of geriatric evaluation and management programs on defined outcomes: Overview of the evidence. J Am Geriatr Soc. 39(Suppl): 8S–18S. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Sun CL, Kim H, Chung V, Koczywas M, Fakih M, Chao J, Chien L, Charles K, dos Hughes SFS, et al: Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial. J Clin Oncol. 38:120102020. View Article : Google Scholar | |
|
Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P, Martin FC, Wang Y and Harari D: The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 112:1435–1444. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mangoni AA and Jackson SH: Age-related changes in pharmaco-kinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 57:6–14. 2004. View Article : Google Scholar | |
|
Cashman J, Wright J and Ring A: The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 18:651–655. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Steinman MA and Hanlon JT: Managing medications in clinically complex elders: 'There's got to be a happy medium'. JAMA. 304:1592–1601. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, et al: Association of proton pump inhibitors and capecitabine efficacy in advanced gastro-esophageal cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 3:767–773. 2017. | |
|
Mislang AR, Di Donato S, Hubbard J, Krishna L, Mottino G, Bozzetti F and Biganzoli L: Nutritional management of older adults with gastrointestinal cancers: An International society of geriatric oncology (SIOG) review paper. J Geriatr Oncol. 9:382–392. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, et al: Prevalence, risk factors and clinical implications of malnutrition in french comprehensive cancer centres. Br J Cancer. 102:966–971. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Andreyev HJN, Norman AR, Oates J and Cunningham D: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 34:503–509. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ross P, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE and O'Brien ME: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 90:1905–1911. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Persson C and Glimelius B: The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res. 22:3661–3668. 2002. | |
|
Bozzetti F; SCRINIO Working Group: Screening the nutritional status in oncology: A preliminary report on 1,000 outpatients. Support Care Cancer. 17:279–284. 2009. View Article : Google Scholar | |
|
Doherty TJ: Invited Review: Aging and sarcopenia. J Appl Physiol (1985). 95:1717–1727. 2003. View Article : Google Scholar | |
|
Rémond D, Shahar DR, Gille D, Pinto P, Kachal J, Peyron MA, Dos Santos CN, Walther B, Bordoni A, Dupont D, et al: Understanding the gastrointestinal tract of the elderly to develop dietary solutions that prevent malnutrition. Oncotarget. 6:13858–13898. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu M, Zhou YX, Jin Y, Wang ZX, Wei XL, Han HY, Ye WF, Zhou ZW, Zhang DS, Wang FH, et al: Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer. 23:1933–1939. 2015. View Article : Google Scholar | |
|
Hurria A, Brogan K, Panageas KS, Jakubowski A, Zauderer M, Pearce C, Norton L, Howard J and Hudis C: Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Drugs Aging. 22:709–715. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hall PS, Swinson D, Waters JS, Wadsley J, Falk S, Roy R, Tillett T, Nicoll J, Cummings S, Grumett SA, et al: Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. J Clin Oncol. 37:40062019. View Article : Google Scholar | |
|
Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ III and Balducci L: Predicting the risk of chemotherapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 118:3377–3386. 2012. View Article : Google Scholar | |
|
Zhang J, Liao X, Feng J, Yin T and Liang Y: Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. Oncol Lett. 18:4947–4955. 2019.PubMed/NCBI | |
|
Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, Ballman K, et al: End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer-Alliance for clinical trials in oncology-international society of geriatric oncology position article. J Clin Oncol. 31:3711–3718. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, et al: Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer:. Results of a phase II trial BMC Cancer. 6:1252006. | |
|
Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, et al: A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 99:584–590. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
di Bartolomeo M, Bajetta E, de Braud F, Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G and Cozzaglio L: Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology. 52:41–44. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Cascinu S, Fedeli A and Catalano G: Etoposide, leucovorin, 5-fluo-rouracil and interferon alpha-2b in elderly gastric cancer patients: A pilot study. Cancer Chemother Pharmacol. 34:72–74. 1994. View Article : Google Scholar | |
|
Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y and Hill M: A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol. 13:1568–1575. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR and Alberts SR: Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 36:601–606. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, et al: Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD. 08–02. Cancer Chemother Pharmacol. 75:319–324. 2015. View Article : Google Scholar | |
|
Smyth EC, Verheij M, Allum W, Cunningham D and Cervantes A: Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27(Suppl 5): v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE, et al: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. Lancet. 377:1749–1759. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Salati M, Di Emidio K, Tarantino V and Cascinu S: Second-line treatments: Moving towards an opportunity to improve survival in advanced gastric cancer? ESMO. Open 2:e0002062017. View Article : Google Scholar | |
|
Sugimoto A, Nishida T, Osugi N, Takahashi K, Mukai K, Nakamatsu D, Matsubara T, Hayashi S, Yamamoto M, Nakajima S, et al: Prediction of survival benefit when deciding between chemotherapy and best supportive therapy in elderly patients with advanced gastric cancer: A retrospective cohort study. Mol Clin Oncol. 10:83–91. 2019.PubMed/NCBI | |
|
Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, Wakabayashi M, Nomura S, et al: An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706). J Clin Oncol. 38:3742020. View Article : Google Scholar | |
|
Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, et al: Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15:894–904. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G and Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol. 15:78–86. 2014. View Article : Google Scholar | |
|
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, et al: Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19:1437–1448. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Parikh JD, Hollingsworth KG, Wallace D, Blamire AM and MacGowan GA: Normal age-related changes in left ventricular function: Role of afterload and subendocardial dysfunction. Int J Cardiol. 223:306–312. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014. View Article : Google Scholar | |
|
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Elias R, Morales J, Rehman Y and Khurshid H: Immune check-point inhibitors in older adults. Curr Oncol Rep. 18:472016. View Article : Google Scholar | |
|
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Adamson D, Byrne A, Porter C, Blazeby J, Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons D, et al: Palliative radiotherapy after oesophageal cancer stenting (ROCS): A multi-centre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. Feb 18–2021.Epub ahead of print. View Article : Google Scholar | |
|
Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, et al: Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: A Phase III randomized controlled trial. J Clin Oncol. 39:748–756. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lord SR, Hall PS and Seymour MT: Are we representing the true population in oncology trials? Ann Oncol. 20:20222009. View Article : Google Scholar : PubMed/NCBI | |
|
Hempenius L, Slaets JP, Boelens MA, van Asselt DZ, de Bock GH, Wiggers T and van Leeuwen BL: Inclusion of frail elderly patients in clinical trials: Solutions to the problems. J Geriatr Oncol. 4:26–31. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Whelehan S, Lynch O, Treacy N, Gleeson C, Oates A and O'Donovan A: Optimising clinical trial design in older cancer patients. Geriatrics (Basel). 3:342018. View Article : Google Scholar | |
|
Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, Magnuson A, Lichtman SM, Bruinooge SS, Soto-Perez-de-Celis E, et al: Improving the evidence base for treating older adults with cancer: American society of clinical oncology statement. J Clin Oncol. 33:3826–3833. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, et al: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI |
